Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
Introduction Relationships between glycemic-lowering effects of sodium glucose co-transporter 2 inhibitors and impact on kidney and cardiovascular outcomes are uncertain.Research design and methods We analyzed 4395 individuals with prebaseline and postbaseline hemoglobin A1c (HbA1c) randomized to ca...
Main Authors: | Bernard Zinman, Bruce Neal, George L Bakris, Vlado Perkovic, Meg J Jardine, Kris Rogers, Jie Yu, Adeera Levin, Dick de Zeeuw, Hong Zhang, Kenneth W Mahaffey, Clare Arnott, Rajiv Agarwal, Gian Luca Di Tanna, Carol Pollock, David C Wheeler, Christopher P Cannon, David M Charytan, Hiddo J Lambers Heerspink, Norman Rosenthal |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-05-01
|
Series: | BMJ Open Diabetes Research & Care |
Online Access: | https://drc.bmj.com/content/11/3/e003270.full |
Similar Items
-
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
by: Jing‐Wei Li, et al.
Published: (2022-08-01) -
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
by: Robert A. Fletcher, et al.
Published: (2023-07-01) -
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial
by: Tamara K. Young, et al.
Published: (2022-01-01) -
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial
by: Abhinav Sharma, et al.
Published: (2024-02-01) -
Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
by: Taha Sen, et al.
Published: (2021-12-01)